Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules

3.3. Biologics
3.3.1. Type of Biologics
3.3.1.1. Peptides
3.3.1.2. Monoclonal Antibodies
3.3.1.3. Gene Therapies
3.3.1.4. Growth Factors
3.3.1.5. Hormones
3.3.1.6. Enzymes
3.3.1.7. Vaccines
3.3.1.8. Blood and Related Products

3.3.2. Regulatory Considerations

3.3. Competition from Biosimilars
3.4. Key Market Drivers and Associated Trends

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Top Selling Biologics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Number of Top Selling Biologics
4.3. Top Selling Biologics: Market Landscape
4.3.1. Analysis by Type of Biologic
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Target Antigen / Gene
4.3.4. Analysis by Type of Biologic and Route of Administration
4.3.5. Analysis by Type of Biologic and Target Antigen / Gene
4.4. Information on Dose Strength and Type of Packaging
4.5. Top Selling Biologics: Key Disease Indications
4.5.1. Analysis by Key Indications
4.6.1 Top Selling Biologics: Target Therapeutic Areas
4.6.2. Analysis by Type of Oncological Disorder
4.6.3. Analysis by Type of Metabolic Disorder
4.6.3.1. Analysis by Type of Autoimmune Disorder
4.6.3.2. Analysis by Type of Gastrointestinal Disorder
4.6.3.3. Analysis by Type of Ophthalmic Disorder
4.6.3.4. Analysis by Type of CNS / Neurological Disorder
4.6.3.5. Analysis by Type of Cardiovascular Disorder
4.6.3.6. Analysis by Type of Blood Disorder
4.6.3.7. Analysis by Type of Respiratory Disorder
4.6.3.8. Analysis by Type of Bone Disorder

5. GLOBAL SALES ANALYSIS OF TOP SELLING BIOLOGICS
5.1. Chapter Overview
5.2. Top Selling Biologics: Global Sales (2020)
5.2.1. Analysis of Global Sales by Type of Biologic
5.2.2. Analysis of Global Sales by Developer
5.2.3. Genentech / Roche: Portfolio of Top Selling Biologics
5.2.3.1. Genentech / Roche: Historical sales of Top Selling Enzymes
5.2.3.2. Genentech / Roche: Historical sales of Top Selling Monoclonal Antibodies
5.2.3.3. Genentech / Roche: Historical sales of Top Selling Hormones
5.2.3.4. Genentech / Roche: Historical sales of Top Selling Other Biologics
5.2.4. AbbVie: Portfolio of Top Selling Biologics
5.2.4.1. AbbVie: Historical sales of Top Selling Monoclonal Antibodies
5.2.4.2. AbbVie: Historical sales of Top Selling Fusion Proteins
5.2.5. Janssen Biotech / Johnson & Johnson: Portfolio of Top Selling Biologics
5.2.5.1. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Monoclonal Antibodies
5.2.5.2. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Hormones
5.2.6. Merck: Portfolio of Top Selling Biologics
5.2.6.1. Merck: Historical sales of Top Selling Hormones
5.2.6.2. Merck: Historical sales of Top Selling Monoclonal Antibodies
5.2.6.3. Merck: Historical sales of Top Selling Vaccines
5.2.7. Amgen: Portfolio of Top Selling Biologics
5.2.7.1. Amgen: Historical sales of Top Selling Monoclonal Antibodies
5.2.7.2. Amgen: Historical sales of Top Selling Hormones
5.2.7.3. Amgen: Historical sales of Top Selling Hormones
5.2.8. Eli Lilly: Portfolio of Top Selling Biologics
5.2.8.1. Eli Lilly: Historical sales of Top Selling Monoclonal Antibodies
5.2.8.2. Eli Lilly: Historical sales of Top Selling Hormones
5.2.8.3. Eli Lilly: Historical sales of Top Selling Fusion Proteins
5.2.9. Sanofi: Portfolio of Top Selling Biologics
5.2.9.1. Sanofi: Historical sales of Top Selling Monoclonal Antibodies
5.2.9.2. Sanofi: Historical sales of Top Selling Enzymes
5.2.9.3. Sanofi: Historical sales of Top Selling Hormones
5.2.10. Bristol Myers Squibb: Portfolio of Top Selling Biologics
5.2.10.1. Bristol Myers Squibb: Historical sales of Top Selling Monoclonal Antibodies
5.2.10.2. Bristol Myers Squibb: Historical sales of Top Selling Fusion Proteins
5.2.11. Novo Nordisk: Portfolio of Top Selling Biologics
5.2.11.1. Novo Nordisk: Historical sales of Top Selling Hormones
5.2.12. Novartis: Portfolio of Top Selling Biologics
5.2.12.1. Novartis: Historical sales of Top Selling Monoclonal Antibodies
5.2.13. Alexion Pharmaceuticals: Portfolio of Top Selling Biologics
5.2.13.1. Alexion Pharmaceuticals: Historical sales of Top Selling Monoclonal Antibodies
5.2.13.2. Alexion Pharmaceuticals: Historical sales of Top Selling Enzymes
5.2.14. AstraZeneca: Portfolio of Top Selling Biologics
5.2.14.1. AstraZeneca: Historical sales of Top Selling Monoclonal Antibodies
5.2.15. Biogen: Portfolio of Top Selling Biologics
5.2.15.1. Biogen: Historical sales of Top Selling Monoclonal Antibodies
5.2.15.2. Biogen: Historical sales of Top Selling Gene Therapy
5.2.16. UCB: Portfolio of Top Selling Biologics
5.2.16.1. UCB: Historical sales of Top Selling Monoclonal Antibodies
5.2.17. GlaxoSmithKline: Portfolio of Top Selling Biologics
5.2.17.1. GlaxoSmithKline: Historical sales of Top Selling Monoclonal Antibodies
5.2.18. Biomarin: Portfolio of Top Selling Biologics
5.2.18.1. Biomarin: Historical sales of Top Selling Enzymes
5.2.19. Bayer: Portfolio of Top Selling Biologics
5.2.19.1. Bayer: Historical sales of Top Selling Interferons

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Top Selling Biologics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Recruitment Status
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Patient Segment
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Leading Organizations: Analysis by Number of Registered Trials
6.3.8. Analysis by Target Therapeutic Area
6.3.9. Analysis by Key Biologics

7. PROMOTIONAL ANALYSIS
7.1. Context and Background
7.2. Top Selling Biologics: Product Website Analysis
7.3. Top Selling Biologics: Patient Support-related Services Provided for Top Selling Biologics
7.4. Humira?: Promotional Analysis
7.4.1. Product Website Analysis
7.4.1.1. Messages for Healthcare Professionals
7.4.1.2. Messages for Patients
7.4.1.3. Informative Downloads
7.4.2. Patient Support Services
7.4.3. Advertisements
7.5. Keytruda?: Promotional Analysis
7.5.1. Product Website Analysis
7.5.1.1. Messages for Healthcare Professionals
7.5.1.2. Messages for Patients
7.5.1.3. Informative Downloads
7.5.2. Patient Support Services
7.5.3. Advertisements
7.6. Opdivo?: Promotional Analysis
7.6.1. Product Website Analysis
7.6.1.1. Messages for Healthcare Professionals
7.6.1.2. Messages for Patients
7.6.1.3. Informative Downloads
7.6.2. Patient Support Services
7.6.3. Advertisements
7.7. Avastin?: Promotional Analysis
7.7.1. Product Website Analysis
7.7.1.1. Messages for Healthcare Professionals
7.7.1.2. Messages for Patients
7.7.1.3. Informative Downloads
7.7.2. Patient Support Services
7.8. Rituxan?: Promotional Analysis
7.8.1. Product Website Analysis
7.8.1.1. Messages for Healthcare Professionals
7.8.1.2. Messages for Patients
7.8.1.3. Informative Downloads
7.8.2. Patient Support Services
7.9. Stelara?: Promotional Analysis
7.9.1. Product Website Analysis
7.9.1.1. Messages for Healthcare Professionals
7.9.1.2. Messages for Patients
7.9.1.3. Informative Downloads
7.9.2. Patient Support Services
7.9.3 Advertisements
7.10. Herceptin: Promotional Analysis
7.10.1. Product Website Analysis
7.10.1.1. Messages for Healthcare Professionals
7.10.1.2. Messages for Patients
7.10.1.3. Informative Downloads
7.10.2. Patient Support Services
7.11. Enbrel: Promotional Analysis
7.11.1. Product Website Analysis
7.11.1.1. Messages for Healthcare Professionals
7.11.1.2. Messages for Patients
7.11.1.3. Informative Downloads
7.11.2. Patient Support Services
7.11.3. Advertisements
8. PRODUCT LIFECYCLE MANAGEMENT STRATEGIES
8.1. Introduction
8.2. Key LCM Strategies
8.2.1. Geographical Expansion
8.2.2. Approval for Additional Disease Indications
8.2.3. Reformulations
8.2.4. Combination Therapies
8.2.5. Exploiting Alternate Routes of Administration
8.2.6. Reimbursement Programs
8.2.6.1. Humira?
8.2.6.2. Keytruda?
8.2.6.3. Opdivo?
8.2.6.4. Avastin?
8.2.6.5. Rituxan?
8.2.6.6. Stelara?
8.2.6.7. Herceptin?
8.2.6.8. Enbrel?
8.2.6.9 Remicade?
8.2.6.10 Trulicity?
8.2.7. Pricing Strategies
8.2.7.1. Humira?
8.2.7.2. Keytruda?
8.2.7.3. Opdivo?
8.2.7.4. Avastin?
8.3. Concluding Remarks

9. COST PRICE ANALYSIS
9.1. Chapter Overview
9.2. Factors Contributing to the Price of Biologics
9.3. Annual Treatment Cost of Top Selling Biologics
9.3.1. Price Comparison across Target Therapeutic Areas
9.3.1.1. Oncological Disorders
9.3.1.2. Metabolic Disorders
9.3.1.3. Autoimmune Disorders
9.3.1.4. Gastrointestinal Disorders
9.3.1.5. Ophthalmic Disorders
9.3.1.6. CNS / Neurological Disorders
9.3.1.7. Cardiovascular Disorders
9.3.1.8. Blood Disorders
9.3.1.9. Respiratory Disorders
9.3.1.10. Bone Disorders
9.4 Concluding Remarks

10. BIOSIMILARS
10.1. Chapter Overview
10.2. Introduction to Biosimilars
10.3. Need For Biosimilars
10.4. Biosimilars of Top Selling Biologics
10.4.1. Analysis by Highest Phase of Development
10.4.2. Analysis by Geography
10.4.3. Biosimilar of Top Selling Biologics: Developers Landscape
10.4.3.1. Analysis by Distribution Network
10.4.3.2. Analysis by Location of Headquarters
10.5. Biosimilars VS Top Selling Biologics
10.5.1. Manufacturing
1.5.2. Clinical Trials
10.2.3. Marketing
10.5.4. Safety

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Global Top Selling Biologics Market, 2021-2030
11.4.1. Top Selling Biologics Market: Distribution by Type of Biologic, 2021-2030
11.4.2. Top Selling Biologics Market: Distribution by Key Players, 2021-2030
11.5. Top Selling Biologics Market: Product-wise Sales Forecast
11.3. Top Selling Biologics: Product Wise Forecast
11.3.1. Monoclonal Antibodies
11.3.1.1. Actemra?
11.3.1.2. Avastin?
11.3.1.3. Benlysta?
11.3.1.4. Cosentyx?
11.3.1.5. Cyramza?
11.3.1.6. Darzalex?
11.3.1.7. Dupixent?
11.3.1.8. Erbitux?
11.3.1.9. Fasenra?
11.3.1.10. Gazyva?
11.3.1.11. Hemlibra?
11.3.1.12. Herceptin?
11.3.1.13. Humira?
11.3.1.14. Ilaris?
11.3.1.15. Imfinzi?
11.3.1.16. Keytruda?
11.3.1.17. Lucentis?
11.3.1.18. Nucala?
11.3.1.19. Ocrevus?
11.3.1.20. Opdivo?
11.3.1.21. Perjeta?
11.3.1.22. Prolia?
11.3.1.23. Remicade?
11.3.1.24. Repatha?
11.3.1.25. Rituxan?
11.3.1.26. Soliris?
11.3.1.27. Stelara?
11.3.1.28. Synagis?
11.3.1.29. Taltz?
11.3.1.30. Tecentriq?
11.3.1.31. Tremfya?
11.3.1.32. Tysabri?
11.3.1.33. Vectibix?
11.3.1.34. Xgeva?
11.3.1.35. Xolair?
11.3.1.36. Yervoy?
11.3.2. Hormones
11.3.2.1. Forteo?
11.3.2.2. Gonal-f?
11.3.2.3. Humalog?
11.3.2.4. Humulin?
11.3.2.5. Lantus?
11.3.2.6. Levemir?
11.3.2.7. Mircera?
11.3.2.8. Neulasta?
11.3.2.9. Novolog?
11.3.2.10. Procrit / Eprex?
11.3.2.11. Toujeo?
11.3.2.12. Tresiba?
11.3.2.13. Victoza?
11.3.3. Enzymes
11.3.3.1. Activase?
11.3.3.2. Fabrazyme?
11.3.3.3. Myozyme?
11.3.3.4. Pulmozyme?
11.3.3.5. Strensiq?
11.3.3.6. Vimizim?
11.3.4. Fusion Proteins
11.3.4.1. Aranesp?
11.3.4.2. Botox?
11.3.4.3. Enbrel?
11.3.4.4. Epogen?
11.3.4.5. Orencia?
11.3.4.6. Trulicity?
11.3.5. Interferons
11.3.5.1. Avonex / Rebif?
11.3.5.2. Betaseron?
11.3.5.3. Kadcyla?
11.3.6. Gene therapies
11.3.6.1. Spinraza?
11.3.7. Antibody fragments
11.3.7.1. Cimzia?
11.3.8. Vaccines
11.3.8.1. Varivax?

12. CONCLUSION

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS